Table 1. Baseline demographic, clinical, and laboratory characteristics of 196 patients with COVID-19.
| Characteristics | Total (n=196) | Non-CV complication (n=142) | CV complication (n=54) | P -value |
| Age, median (IQR), y | 65 (52-77) | 65 (54.25-76.75) | 65 (43.25-77.5) | 0.713 |
| Male, No. (%) | 104 (53.1) | 73 (51.4) | 31 (57.4) | 0.452 |
| Comorbidities | ||||
| Diabetes, No. (%) | 34 (17.3) | 22 (15.5) | 12 (22.2) | 0.266 |
| Hypertension, No. (%) | 105 (53.6) | 79 (55.6) | 26 (48.1) | 0.348 |
| Coronary artery disease, No. (%) | 37 (18.9) | 29 (20.4) | 8 (14.8) | 0.370 |
| Heart failure, No. (%) | 47 (24) | 35 (24.6) | 12 (22.2) | 0.722 |
| Chronic obstructive pulmonary disease, No. (%) | 17 (8.7) | 13 (9.2) | 4 (7.4) | 1 |
| Cancer/autoimmune disease, No. (%) | 13 (6.6) | 12 (8.5) | 1 (1.9) | 0.118 |
| Chronic kidney disease, No. (%) | 7 (36) | 5 (3.5) | 2 (3.7) | 1 |
| Number of comorbidities | ||||
| 0 | 40 (20.4) | 29 (20.4) | 11 (20.4) | 0.111 |
| 1 | 67 (34.2) | 42 (29.6) | 25 (46.3) | |
| 2 | 74 (37.8) | 60 (42.3) | 14 (25.9) | |
| 3 | 15 (7.7) | 11 (7.7) | 4 (7.4) | |
| Clinical Presentation | ||||
| Dyspnea, No. (%) | 129 (65.8) | 98 (69) | 31 (57.4) | 0.126 |
| Chest pain, No. (%) | 5 (2.6) | 2 (1.4) | 3 (5.6) | 0.129 |
| Fever, No. (%) | 38 (23.8) | 31 (25.4) | 7 (18.4) | 0.377 |
| Systolic blood pressure, mean (SD), mmHg | 117.5 (106.25-138) | 115 (110-130) | 120 (100-140) | 0.519 |
| Heart rate, median (IQR) | 82 (76.25-100) | 82 (78-99) | 84 (72-100) | 0.715 |
| Respiratory rate, median (IQR) | 20 (18-23.5) | 20 (18-23) | 20 (18-24) | 0.982 |
| Blood oxygen saturation, median (IQR), percent | 93 (88-96) | 93 (88-96.5) | 93 (88-96) | 0.771 |
| Medication History | ||||
| Aspirin, No. (%) | 76 (38.8) | 56 (39.4) | 20 (37) | 0.758 |
| Atorvastatin, No. (%) | 75 (38.3) | 55 (38.7) | 20 (37) | 0.827 |
| angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, No. (%) | 74 (37.8) | 56 (39.4) | 18 (33.3) | 0.431 |
| Anticoagulant, No. (%) | 23 (11.7) | 15 (10.6) | 8 (14.7) | 0.409 |
| Furosemide, No. (%) | 32 (16.3) | 24 (16.9) | 8 (14.8) | 0.724 |
| Novel oral anticoagulant, No. (%) | 4 (2) | 3 (2.1) | 1 (1.9) | 1 |
| Laboratory | ||||
| Leukocytes, median (IQR), /μL | 9800 (7450-13050) | 9700 (6800-12525) | 10100 (8000-13900) | 0.150 |
| Platelets, median (IQR), ×103/μL | 208 (154-282) | 212(154.5-277.2) | 192 (153-310) | 0.798 |
| Erythrocyte sedimentation rate, median (IQR), percent | 45 (25-82.75) | 50 (22.5-82.5) | 70 (38-100) | 0.036* |
| Creatinine, median (IQR), mg/dL | 1.2 (0.85-2) | 1 (0.85-1.7) | 1.3 (1-2) | 0.181 |
| Blood urea, median (IQR), mg/dL | 27 (16-49.25) | 25 (16-47) | 34 (25-58) | 0.065 |
| Raised high-sensitivity Troponin I, No. (%) | 27 (13.8) | 5 (3.5) | 22 (40.7) | <0.001 |
| C-reactive protein, median (IQR), mg/dL | 70 (19-123.5) | 71 (20.5-145) | 140 (67-190) | 0.041* |
| Raised N-terminal pro-B-type natriuretic peptide, No. (%) | 141 (72) | 96 (67.6) | 45 (83.3) | 0.029* |
| Procalcitonin, median (IQR), ng/mL | 0.5 (0.1-2.7) | 0.5 (0.1-3) | 0.5 (0.18-3.5) | 0.295 |
| Interleukin-6, median (IQR), pg/mL | 45 (14-126) | 41 (14-120.5) | 46 (13.5-148.25) | 0.675 |
Abbreviation: IQR, interquartile range.